OIS-Generic-Author-Image-MALE

Heather Johnson

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Pharma

March 3 2021

What’s a SPAC? A Route to Public Markets for Gemini Therapeutics

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market ...
Read More

February 10 2021

With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical ...
Read More

January 18 2021

The Strategy Behind EyeGate’s Acquisition of Panoptes

With the acquisition of Vienna-based biotech Panoptes Pharma, Eye Gate Pharmaceuticals has expanded its pipeline of nonsteroidal products targeting ocular inflammation by adding Panoptes’ PP-001, ...
Read More

December 22 2020

Novartis Steps Up Digital Strategy for AMD Treatments and Patient Support

Novartis is doubling down on its mission to end preventable blindness, which has translated into a host of moves to strengthen its commitment to age-related ...
Read More

November 3 2020

Equinox Founder Berdahl Moves Sideways, But Not Away, to Keep Company Growing

While scuba diving in the Caribbean, John Berdahl, MD, came up with the idea that led him to found Equinox. Five years later, that company ...
Read More

October 6 2020

Opthea’s Activity Leads to IPO

Opthea, the Australia-based biopharma developing a novel therapy to treat exudative retinal diseases, closed out a busy summer with a US Securities and Exchange Commission ...
Read More

September 8 2020

Kubota’s Smart Glasses Aim to Slow Myopia Progression

They won’t help you search the Internet, but Kubota Vision’s glasses may help slow the progression of myopia, and possibly even prevent the condition when ...
Read More

September 1 2020

The COVID Effect: Q2 Was Tough, Q3 Is Looking Up

Ophthalmology drugs, particularly drugs associated with surgeries and retinal disease, took a beating in Q2 because of COVID-19 disruptions. Things may be looking up for ...
Read More
Emerging Glaucoma Devices See Beyond IOP

May 27 2020

Emerging Glaucoma Devices See Beyond IOP

The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and ...
Read More
9 Steps to Launching a Product

March 3 2020

9 Steps to Launching a Product

Editor's Note: The FDA just approved Allergan's Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on ...
Read More
Glaucoma 360: Promising data as the industry considers value

February 12 2020

Glaucoma 360: Promising data as the industry considers value

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...
Read More
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

March 19 2019

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make ...
Read More